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OBJECTIVE — Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX)
syndrome is caused by FOXP3 mutations. We aimed to determine the prevalence, genetics, and
clinical phenotype of FOXP3 mutations in a large cohort with permanent neonatal diabetes
(PNDM).
RESEARCH DESIGN AND METHODS — The 11 coding exons and the polyadenyla-
tion region of FOXP3 were sequenced in 26 male subjects with diabetes diagnosed before 6
months of age in whom common genetic causes of PNDM had been excluded. Ten subjects had
at least one additional immune-related disorder, and the remaining 16 had isolated diabetes.
RESULTS — We identiﬁed four hemizygous FOXP3 mutations in 6 of 10 patients with asso-
ciatedimmune-relateddisordersandin0of16patientswithisolateddiabetes(P0.002).Three
patients with two novel mutations (R337Q and P339A) and the previously reported L76QfsX53
developed classic IPEX syndrome and died within the ﬁrst 13 months. The novel mutation
V408M was found in three patients from two unrelated families and had a mild phenotype with
hypothyroidism and autoimmune enteropathy (n  2) or nephrotic syndrome (n  1) and
survival to 12–15 years.
CONCLUSIONS — FOXP3 mutations result in 4% of cases of male patients with perma-
nent diabetes diagnosed before 6 months. Patients not only have classic IPEX syndrome but,
unexpectedly, may have a more benign phenotype. FOXP3 sequencing should be performed in
anymalepatientwiththediagnosisofdiabetesintheﬁrst6monthswhodevelopsotherpossible
autoimmune-associated conditions, even in the absence of full IPEX syndrome.
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T
ype1diabetesistheleadingcauseof
diabetes among children except for
thoseinwhomdiabetesisdiagnosed
before the age of 6 months. HLA studies
have shown that patients in whom diabe-
tes is diagnosed within the ﬁrst 6 months
of life (permanent neonatal diabetes
[PNDM]) do not harbor high-risk HLA
haplotypes and hence are very unlikely to
have classic type 1 diabetes (1,2). These
patients should be tested for monogenic
causes of neonatal diabetes.
Mutations in FOXP3 have been asso-
ciated with a severe, early-onset, male-
limited autoimmunity syndrome known
as IPEX (immune dysregulation, polyen-
docrinopathy, enteropathy, X-linked;
OMIM [Online Mendelian Inheritance in
Man] 304930) (3–5). The gene maps to
chromosome Xp11.23 and encodes a
431–amino acid protein, also named
scurﬁn, required for the generation and
functioning of CD4
CD25
 regulatory T
lymphocytes.FOXP3-expressingCD4
T
cells are potent suppressors of self-
reactive T-cell activation and prolifera-
tion, presumably via direct cell-cell
interaction. Thus, lack of these cells re-
sults in an uncontrolled autoimmune re-
activity in male patients with hemizygous
FOXP3 mutations (6). In keeping with an
X-linked recessive mode of inheritance,
heterozygouscarrierfemalesremaincom-
pletely asymptomatic, but each son has a
50% risk of being affected with IPEX syn-
drome. One patient with IPEX syndrome
due to recessive inheritance of CD25 mu-
tations has recently been reported (7).
Most patients with IPEX syndrome
described to date have developed symp-
toms shortly after birth or during the ﬁrst
3–4 months of life. The most common
ﬁndings have been enteropathy (nearly
100%ofpatients),diabetes(70%),skin
disease (65%), failure to thrive
(50%), thyroiditis (30%), and recur-
rent infections (20%). Less common
additional features include autoimmune
cytopenias, pneumonitis, nephritis, hep-
atitis,vasculitis,arthritis,myositis,andal-
opecia as well as lymphadenopathy and
splenomegaly. These disorders often ap-
pear sequentially rather than simulta-
neously, and the affected organ spectrum
variessubstantiallyfrompatienttopatient
(8). The life expectancy of patients with
IPEX syndrome rarely extends beyond
infancy.
However, a milder phenotype has
been reported in a number of patients,
who can live longer, sometimes into
adulthood. Enteropathy was present in
virtually all of them, although diabetes
was frequently absent (9–11).
To our knowledge, FOXP3 has not
been systematically studied before in pa-
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we aimed to explore the prevalence of
FOXP3 mutations in the largest world-
wide cohort of PNDM.
RESEARCH DESIGN AND
METHODS— This study was con-
ducted in accordance with the Declara-
tion of Helsinki, as revised in 2000.
Informed consent was obtained from all
patients, with parental consent given on
behalf of children.
Thestudypopulationoriginatedfrom
the International Society of Pediatric and
Adolescent Diabetes (ISPAD) Rare Diabe-
tes Study. In total, 296 patients (154
boys) with diabetes diagnosed in the ﬁrst
6 months of life who were receiving insu-
lin treatment at the time of referral were
studied. A genetic cause for the disease
had previously been identiﬁed in 171
subjects:KCNJ11in85patients,INSin37
patients, ABCC8 in 30 patients, GCK in 8
patients, EIF2AK3 in 8 patients, PTF1A in
2 patients, and IPF1 in 1 patient (12–14;
S.E.,A.T.H.,unpublisheddata).Themost
common causes of PNDM had been ex-
cluded by direct sequencing in the re-
maining 125 patients, 70 of whom were
male. Speciﬁcally, mutations in KCNJ11
had been excluded in 68 patients, ABCC8
mutations had been excluded in 63 pa-
tients, INS mutations had been excluded
in 63 patients, and GCK mutations had
been excluded in 31 patients.
Amongthe70malepatientswithouta
molecular diagnosis, we sequenced
FOXP3 in 10 subjects from 9 unrelated
families on the basis of the presence of
PNDM and any other immune-mediated
disease. As a comparison, we also se-
quenced FOXP3 in 16 further male pa-
tients with PNDM but without any
associated immune disease.
DNA samples were collected in Ex-
eter. Clinical information was obtained
from hospital records with assistance
from the referring clinicians. Pancreatic
autoantibodies were measured locally ac-
cording to the standard clinical practice.
Sequence variants were tested for their
presence in family members whenever a
DNA sample was available.
Molecular genetic analysis
Genomic DNA was extracted from pe-
ripheral leukocytes using standard proce-
dures. The 11 coding exons, minimal
promoter, and the 3-untranslated region
of the FOXP3 gene including the polyad-
enylation signal were ampliﬁed by PCR;
primers and conditions are available
upon request. Sequence-speciﬁc primers
for each amplicon were tagged with 5
M13 tails to allow sequencing to be per-
formed with a “universal” M13 primer.
Single strand sequencing was carried
out using standard methods on an ABI
3730 sequencer (Applied Biosystems,
Warrington, U.K.). Sequences were com-
pared with the published sequence
(NM_014009.3) using Mutation Sur-
veyor (version 3.10). Any changes in the
sequencewerecheckedagainstpublished
polymorphisms and mutations and for
conservation across species.
We used a panel of microsatellites for
chromosome 20q to conﬁrm family rela-
tionships in those families in whom the
mutation seemed to have arisen de novo.
Patients with PNDM and other autoim-
mune disease in whom no FOXP3 muta-
tion was identiﬁed were also investigated
for the presence of CD25 mutations by
sequencing of the coding region.
Molecular models
Predicted three-dimensional structures
for the forkhead DNA-binding domain
(DBD) (residues 335–423) of normal and
variant FOXP3 proteins were generated
using SWISS-MODEL (http://swissmod-
el.expasy.org/), an Internet-based tool for
automatedcomparativeproteinmodeling
(15). Structures were visualized and im-
ages were generated using either MDL
Chime (Symyx Technologies) or Deep-
View (Swiss-PdbViewer) programs (16).
RESULTS
Molecular genetics
We identiﬁed four different mutations in
FOXP3 in six male subjects with PNDM
from ﬁve unrelated families, all of whom
presented with an associated immune-
mediateddisease(seebelow).Noneofthe
16 patients with isolated PNDM had a
variant in the FOXP3 sequence (Fisher’s
exact test; P  0.002). No CD25 muta-
tions were identiﬁed in probands lacking
FOXP3 mutations.
There were three novel FOXP3 mis-
sense mutations: R337Q (c.1010GA;
p.Arg337Gln), P339A (c.1015CG;
p.Pro339Ala), and V408M (c.1222GA;
p.Val408Met), the latter being present in
three patients (including monozygotic
twins) from two unrelated pedigrees (Fig.
1). The affected amino acid residues were
conservedamongspeciesaswellasinsev-
eral other members of the forkhead tran-
scription factor superfamily (data not
shown). None of them was found in 510
European Caucasian or in 147 Turkish
control X chromosomes. Only one of the
mutations had previously been reported
(c.227delT; p.Leu76GlnfsX53). It intro-
ducesaframeshiftandgeneratesaprema-
ture stop codon (17,18). The inheritance
within families of the mutations is in
keeping with an X-linked inheritance as
shown in Fig. 1.
Clinical features
The clinical information from patients
bearing a FOXP3 mutation is shown in
Figure 1—Pedigrees for families with individuals harboring a FOXP3 mutation. Filled symbols
represent patients with early-onset diabetes; black dots represent asymptomatic female carriers.
The genotype is shown underneath each symbol; M and N denote mutant and wild-type alleles,
respectively. An arrow indicates the proband.
FOXP3 mutations in permanent neonatal diabetes
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differences (including age at diabetes on-
set, birth weight, or type of associated au-
toimmune disease) between those who
werepositiveandnegativeforFOXP3mu-
tations (data not shown). Classic IPEX
syndrome was present in three of the six
patients, all of whom died by 13 months.
In contrast, all three patients with the
V408Mmutationhadamilderphenotype
as well as prolonged survival (still alive at
age 12–15 years).
Diabeteswasthepresentingfeaturein
all subjects. Age at diagnosis varied from
the ﬁrst day of life to 3.5 months and did
not correlate with the outcome of the dis-
ease. Birth weight was a feature of disease
severity as it was markedly reduced only
in the two patients who died early in in-
fancy. Antibodies against -cell antigens
were reported to be unequivocally
present in just one patient; in this patient
results were negative at the time diabetes
was diagnosed and became positive only
during follow-up.
Gastrointestinal symptoms devel-
oped in ﬁve of six patients, although both
the timing and the clinical severity varied
widely. Interestingly, one of the most se-
verely affected infants (Table 1, proband
V) had diarrhea with low fecal elastase,
and a magnetic resonance imaging (MRI)
scan performed at 4 months showed only
a tiny remnant of pancreatic tissue (Fig.
2). Thyroid disease was also found in ﬁve
of six patients, but again it ranged be-
tween very mildly elevated thyroid-
stimulating hormone levels without any
detectable thyroid antibodies to severe
autoimmune hypothyroidism. Proband I
(hemizygous for V408M) did not have
any gastrointestinal problem and only
had a steroid-sensitive nephrotic syn-
drome that was considered to represent
minimal change disease by the attending
nephrologist.
Molecular models
Inspection of the predicted structures of
the DBD of FOXP3 suggested that all
three novel missense FOXP3 mutations
are likely to have deleterious effects on
protein function and therefore be patho-
genic, although to various degrees. In
normal FOXP3, the side chain of arginine
337 is predicted to make close contact
with the DNA backbone (Fig. 3A, top
panel). The presence of a strong basic res-
idue at this position is conserved in all
forkheadtranscriptionfactors,anditcon-
tributes to DNA binding through both
hydrogenbondingandelectrostaticinter-
actions. The R337Q substitution destroys
thisclosecontactwiththeDNAbackbone
(Fig. 3A, bottom panel) and is predicted to
cause a signiﬁcant loss of positive charge
at the DNA-binding surface of FOXP3
(Fig. 3B). Taken together, the data
stronglysuggestthattheR337Qmutation
will result in a signiﬁcant loss of DNA
binding afﬁnity.
Proline 339 lies in a 	-turn between
Arg
337 and helix 1 of the DBD. Substitu-
tion of this residue by alanine (as in the
P339A mutation) is likely to affect the to-
pology of Arg
337 and/or helix 1 relative to
theDNAandsowouldalsobeexpectedto
have a deleterious effect on DNA binding
afﬁnity.
Valine 408 lies in a -turn at the
COOH-terminal of wing 1; in the pre-
dicted structure of FOXP3 its side chain
points away from the DNA-binding sur-
face and toward the side chain of arginine
347 in helix 1 (data not shown), although
there is no apparent contact between the
two side chains. Interestingly, replacing
Val
408 with the longer methionine is pre-
dicted to allow van der Waals contact be-
tween the two side chains (data not
Figure 2— Abdominal MRI scan showing the absence of recognizable pancreatic tissue in one of
the patients with classic IPEX syndrome (c.227delT, p.Leu74GlnfsX53 mutation). White arrow-
heads point to the pancreas in a control subject.
Figure 3— Predicted structures of the DBD of normal and R337Q FOXP3. A: Predicted interac-
tion of FOXP3 with DNA. FOXP3 is represented in ribbon form, colored blue (NH2-terminal) to
red (COOH-terminal), except for residue 337 (labeled) that shows the van der Waals radii of
backbone and side chain atoms as dotted surfaces (white, carbon; blue, nitrogen; red, oxygen).
Other features referred to in the text (helix 1 and the wing region) are labeled; the main DNA
recognition helix (helix 3, green) lies in the major groove of the DNA. The DNA strand predicted
to contact FOXP3 R337 is represented as a space-ﬁlling model, showing the van der Waals radii
of the backbone atoms (white, carbon; red, oxygen; yellow, phosphorus). For clarity, each of the
second DNA strands is shown only as a stick model of the backbone (blue). B: Molecular surface
ofFOXP3,showingareasofpositive(blue)ornegative(red)electrostaticpotential.Thestructure
shown in A has been rotated upward to look toward the DNA-binding surface; the position of
residue 337 is indicated by the purple oval, and the DNA strands have been omitted for clarity.
Structures were visualized and molecular surfaces were calculated using DeepView (A)o rM D L
Chime (B) programs.
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tween wing 1 and helix 1 is likely to have
some effect on protein ﬂexibility within
the DBD, and it is reasonable to suspect
that reduced ﬂexibility in the DBD of
FOXP3willhaveanimpactonDNAbind-
ing afﬁnity. However, given the weak na-
ture of van der Waals interactions, such
effects are likely to be relatively modest,
and the V408M substitution has no ap-
parent effect either on the predicted hy-
drogen bond between the nearby residue
Tyr
406 and the DNA backbone or on sur-
facechargedistribution(datanotshown).
Therefore, the effects of the V408M sub-
stitution on protein structure are milder
thantheothermutations,whichisconsis-
tent with the mild phenotype observed
among subjects with this mutation.
CONCLUSIONS — Our systematic
search for FOXP3 mutations in a large co-
hort of male probands with PNDM in
whom the common causes had been ex-
cluded has shown that mutations are
common in males who subsequently de-
velop possible immune-mediated disor-
ders(6of10[60%])butareabsentorvery
rareinthosewhohaveisolateddiabetes(0
of16[0%]).Weshowthatthereisclinical
heterogeneity with three of the six muta-
tion carriers having a severe phenotype
and dying by 13 months, whereas the
other three are still alive at 12–15 years.
We report on four different muta-
tions, including three novel mutations.
The previously reported single base pair
deletion at position 227 generates a
frameshift and introduces a premature
stop codon. If the mutant mRNA evades
nonsense-mediated decay, the resulting
proteinwouldlacktheforkheadaswellas
the zinc ﬁnger and the leucine zipper do-
mains and is predicted to be completely
inactive. Consistent with this null muta-
tion, the patient presented with classic
IPEX syndrome and died within the ﬁrst
yearoflife.Thelikelypathogenicityofthe
three novel missense mutations was ex-
plored by using molecular modeling soft-
ware. All of them are located within the
forkhead domain of FOXP3; their pre-
dicted structural effects are likely to alter
functionoftheproteinandcanbebroadly
correlated with the observed phenotype.
The pathogenicity of R337Q is further
supported as a different substitution at
position 337 (R337P) as was previously
described in a patient with IPEX syn-
drome (19). A substitution of asparagine
forasparticacidatposition409ofFOXP3
(adjacent to the site of the V408M muta-
tion) also produces IPEX syndrome (20).
Thus, we believe that the three novel mu-
tations are likely to be responsible for the
observed phenotypes.
Permanent diabetes was the present-
ing feature in the six patients with a
FOXP3 mutation, although age at diagno-
sis varied. There was no correlation be-
tween the age at presentation and the
clinicaloutcomeofthepatients;however,
there was a suggestion that low birth
weight, a reﬂection of intrauterine insulin
secretion,wasaprognosticmarker:twoof
the three patients who died within the
ﬁrst 13 months of life as a result of severe
IPEX syndrome were born with severe in-
trauterine growth retardation. Low birth
weight might be a marker of poor prog-
nosis among patients with FOXP3
mutations.
Autoantibodies against -cell anti-
gens were only persistently found in one
of our six affected children, and in this
child they were not present at diagnosis,
suggesting that the main pathogenic
mechanism leading to -cell destruction
ismediatedbyactivatedTlymphocytes.A
systematic investigation of all possible
-cell autoantibodies was not performed
in these children, and serum was not
available for a retrospective analysis in a
central laboratory. Therefore, the com-
plete lack of antibodies cannot deﬁnitely
be conﬁrmed. However, our results show
that antibodies against -cell proteins as
they are used in routine clinical practice
may be absent in patients with proven
FOXP3 mutations. Thus, the absence of
pancreatic autoantibodies should not be
taken as a screening test to exclude the
possibility of a FOXP3 mutation.
One patient with classic IPEX syn-
drome only had a small remnant of pan-
creatic tissue seen on an abdominal MRI
scan and had evidence of evolving exo-
crine pancreatic dysfunction, suggesting
the development of pancreatic atrophy.
Although both mild pancreatic exocrine
insufﬁciency and a reduced pancreas vol-
ume are relatively common ﬁndings in
long-standingclassictype1diabetes,they
are not as severe as in this patient. It is
possible that a massive autoimmune re-
sponse against the pancreas might be re-
sponsible for both PNDM and pancreatic
atrophyinthispatientasseeninmaternal
enteroviral infection (21).
Therewasconsiderableclinicalheter-
ogeneity among the patients with FOXP3
mutations. Three patients with classic
IPEX syndrome died during the ﬁrst 13
monthsoflifedespitetheuseofimmuno-
suppressive therapy. However, the phe-
notypic spectrum is extended from that
previously described in the three patients
with the V408M mutation. PNDM was
theonlyclinicalfeatureintwotwinbroth-
ers from one of the pedigrees with this
mutation until the age of 1 year, when
autoimmune hypothyroidism was diag-
nosed in both of them. Subsequently,
they both developed recurrent diarrhea,
and autoimmune enteropathy was diag-
nosed on the basis of positive antientero-
cyte antibodies in both twins. They had
multiple antibodies indicating gastroin-
testinal autoimmunity (Table 1). Twin IIa
had a jejunal intestinal biopsy showing
villous atrophy, but the second twin (IIb)
had a normal jejunal biopsy. Interest-
ingly, they both developed very well on a
gluten-free diet. These patients are now
12 years old, and no other signiﬁcant
problems have been detected except that
both have intellectual impairment (IQ of
74 and 80, respectively). The other pa-
tient with a V408M mutation has the
mildest phenotype associated with a
FOXP3mutationtodate.Althoughdiabe-
tes was diagnosed 2 days after birth, no
other evidence of immune dysfunction
has been detected apart from an episode
of nephrotic proteinuria at 6 years. Clini-
cal remission was achieved with steroid
treatment, and the disease has not re-
lapsed. The patient is currently 15 years,
and no other autoimmune problems have
arisen since then. Nephrotic syndrome
and classic type 1 diabetes can be associ-
ated, indicating a shared immunological
basis for both disorders (22,23), and ne-
phrotic syndrome has previously been
described in a patient with classic IPEX
syndrome (24). We therefore believe that
there may be a causal link between both
diabetes and nephrotic syndrome and the
presence of the V408M mutation in our
patient.
IPEX syndrome is thought to be an
extremely rare condition with only ap-
proximately 50 cases reported in the lit-
erature. As with any other X-linked
recessive disorder with reduced survival,
IPEX syndrome frequently presents as a
single case either caused by de novo or
maternally inherited mutations. Patients
withamildpresentationarelikelytohave
been under-reported, so the true inci-
dence of the disease might actually be
higher than is currently perceived. A clin-
ical diagnosis of IPEX syndrome was
made in only one of our patients before
the genetic analysis, whereas the others
were referred for genetic testing because
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trum resulting from mutations in FOXP3
emphasizes the need to be aware of this
possibility in male patients with PNDM
who develop any other immune-
mediated disorder later in life.
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